New cms decision provides medicare coverage for the clinical use of the tempus ecg-af device

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced the impact of a new decision by the centers for medicare and medicaid services (cms) that will allow reimbursement for assessments of cardiac dysfunction using the tempus ecg-af algorithm. ecg-af is one of just a few fda-authorized medical technologies in the country to be impacted by the new cms decision, and this milestone all.
TEM Ratings Summary
TEM Quant Ranking